DOI:
10.1055/s-00000025
Hormone and Metabolic Research
LinksClose Window
References
Hodi FS, Chesney J, Pavlick AC. et al.
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
Lancet Oncol 2016;
17: 1558-1568
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.